PRAMEF7: A Potential Drug Target and Biomarker for the PRAME Family

Target Name: PRAMEF7

NCBI ID: G441871

PRAMEF7

Other Name(s): PRAME family member 7 | PRAM7_HUMAN

PRAMEF7: A Potential Drug Target and Biomarker for the PRAME Family

The PRAME family, which includes PRAMEF1, PRAMEF2, PRAMEF3, PRAMEF4, PRAMEF5, PRAMEF6, and PRAMEF7, is a family of transducing RNA-binding proteins with molecular weights ranging from 11 kDa to 120 kDa. These proteins have multiple functions in organisms, such as cell proliferation, differentiation, and tumorigenesis. Among them, PRAMEF7 is up-regulated in a variety of tumors and up-regulated in a variety of cancer samples. This indicates that PRAMEF7 plays an important role in tumor occurrence and development.

PRAMEF7 is a transducing RNA-binding protein that is mainly responsible for binding newly transcribed mRNA in cells. Up-regulation of PRAMEF7 expression in tumors is associated with the progression and invasion capabilities of various cancers. Phosphorylation of mRNAs bound to PRAMEF7 can lead to the clearance of these mRNAs from cells, thereby inhibiting tumor growth and progression.

In addition, the expression level of PRAMEF7 is also related to the prognosis of various cancers. For example, patients with tumors with lower PRAMEF7 expression levels have higher rates of metastasis and mortality. In contrast, patients with tumors with higher PRAMEF7 expression levels had better prognosis. These findings suggest that PRAMEF7 can serve as a potential drug target or biomarker for predicting prognosis and treatment response in cancer patients.

The pharmacological properties of PRAMEF7 suggest that it has the potential to become a target for tumor treatment. The phosphorylation site of PRAMEF7 is located in a conserved region that recruits phosphorylase enzymes, making PRAMEF7 a good drug target. In addition, the expression level of PRAMEF7 can be used to predict the survival and treatment response of tumor patients. By reducing the expression level of PRAMEF7, the survival and treatment response of tumor patients can be improved.

Based on the pharmacological properties of PRAMEF7, researchers are exploring the possibility of PRAMEF7 as a tumor therapeutic target. Several research groups have discovered antagonists of PRAMEF7 and demonstrated that they can inhibit tumor growth and progression. These antagonists can be administered orally or by injection, providing a new treatment option for cancer patients.

In addition to being a drug target, PRAMEF7 may also be used as a biomarker to predict the survival and treatment response of cancer patients. The expression level of PRAMEF7 can be used to predict the overall survival and progression-free survival of tumor patients. In addition, the expression level of PRAMEF7 can also be used to predict the response rate of cancer patients to treatment. These findings suggest that PRAMEF7 can serve as an effective biomarker for predicting survival and treatment response in cancer patients.

In conclusion, PRAMEF7, as a transducing RNA-binding protein, plays an important role in tumor occurrence and development. Its expression level is related to the progression and invasion ability of tumors, and is related to the prognosis and survival of tumor patients. These findings suggest that PRAMEF7 can serve as a potential drug target or biomarker for predicting survival and treatment response in cancer patients. Future studies will continue to explore the role of PRAMEF7 in tumor treatment and reveal its mechanism of action in tumor biology.

Protein Name: PRAME Family Member 7

The "PRAMEF7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRAMEF7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets